Advanced search
Publication Cover
International Journal of Hyperthermia Volume 39, 2022 - Issue 1
Submit an article Journal homepage
1,534
Views
1
CrossRef citations to date
0
Altmetric
Articles

Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study

Oliver Riesterera Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9508-0546View further author information
ORCID Icon,
Adela Ademaja Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland;b Doctoral Clinical Science Program, Medical Faculty, University of Zürich, Zurich, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-6568-7198View further author information
ORCID Icon,
Emsad Purica Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Brigitte Eberlea Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Marcus Beckc Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyView further author information
,
Silvia Gomeza Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Dietmar Mardera Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandORCID Iconhttps://orcid.org/0000-0003-0865-9283View further author information
ORCID Icon,
Eva Oberackerc Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyORCID Iconhttps://orcid.org/0000-0001-7678-6677View further author information
ORCID Icon,
Susanne Rogersa Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Roger A. Hälga Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland;d Institute of Physics, Science Faculty, University of Zurich, Zurich, SwitzerlandView further author information
,
Thomas Kerna Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Sonja Schwennea Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Jürgen Steine Department of Urology, Bundeswehrkrankenhaus Berlin, Berlin, GermanyView further author information
,
Emanuel Stutza Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland;f Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, SwitzerlandView further author information
,
Olaf Timma Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Sebastian Zschaeckc Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyORCID Iconhttps://orcid.org/0000-0003-3109-0662View further author information
ORCID Icon,
Mathias S. Weylandg ZHAW School of Engineering, Zurich University of Applied Science, Zurich, SwitzerlandORCID Iconhttps://orcid.org/0000-0001-6389-0029View further author information
ORCID Icon,
Paraskevi D. Veltsistac Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyView further author information
,
Stephen Wylerh Department of Urology, Cantonal Hospital Aarau, Aarau, SwitzerlandView further author information
,
Peter Wustc Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyView further author information
,
Stephan Scheideggerg ZHAW School of Engineering, Zurich University of Applied Science, Zurich, SwitzerlandORCID Iconhttps://orcid.org/0000-0002-2622-2918View further author information
ORCID Icon,
Stephan Bodisa Centre for Radiation Oncology KSA-KSB, Cantonal Hospital Aarau, Aarau, Switzerland;i Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, SwitzerlandView further author information
&
Pirus Ghadjarc Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, GermanyORCID Iconhttps://orcid.org/0000-0002-2747-165XView further author information
ORCID Icon show all
Pages 1078-1087 | Received 16 Apr 2022, Accepted 29 Jul 2022, Published online: 21 Aug 2022

References

  • Weiss C, Wolze C, Engehausen DG, et al. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol. 2006;24(15):2318–2324.
  • Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol. 2006;24(35):5536–5544.
  • Merten R, Ott O, Haderlein M, et al. Long-Term experience of chemoradiotherapy combined with deep regional hyperthermia for organ preservation in high-risk bladder cancer (Ta, Tis, T1, T2). Oncologist. 2019;24(12):e1341–e1350.
  • Chauvet B, Brewer Y, Felix-Faure C, et al. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol. 1996;156(4):1258–1262.
  • Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061–3071.
  • James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–1488.
  • George L, Bladou F, Bardou VJ, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology. 2004;64(3):488–493.
  • Hill SA, Denekamp J. The response of six mouse tumours to combined heat and X rays: implications for therapy. Br J Radiol. 1979;52(615):209–218.
  • Overgaard J. Fractionated radiation and hyperthermia: experimental and clinical studies. Cancer. 1981;48(5):1116–1123.
  • Ohtsubo T, Saito H, Tanaka N, et al. Enhancement of cisplatin sensitivity and platinum uptake by 40 degrees C hyperthermia in resistant cells. Cancer Lett. 1997;119(1):47–52.
  • Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21(23):4270–4276.
  • van der Zee J, González D, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch deep hyperthermia group. Lancet. 2000;355(9210):1119–1125.
  • Lagendijk JJ, Van Rhoon GC, Hornsleth SN, et al. ESHO quality assurance guidelines for regional hyperthermia. Int J Hyperthermia. 1998;14(2):125–133.
  • Bruggmoser G, Bauchowitz S, Canters R, et al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol. 2012;188(Suppl 2):198–211.
  • Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984;10(6):787–800.
  • Scott NW, Fayers PM, Aaronson NK, et al. EORTC QLQ-C30 reference values manual. 2nd ed. Brussels, Belgium: EORTC Quality of Life Group; 2008. p. 427.
  • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
  • Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1–10.
  • Peyromaure M, Slama J, Beuzeboc P, et al. Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution. Urology. 2004;63(1):73–77.
  • Wittlinger M, Rödel CM, Weiss C, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol. 2009;93(2):358–363.
  • Kroesen M, Mulder HT, van Holthe JML, et al. Confirmation of thermal dose as a predictor of local control in cervical carcinoma patients treated with state-of-the-art radiation therapy and hyperthermia. Radiother Oncol. 2019;140:150–158.
  • Bakker A, Tello Valverde CP, van Tienhoven G, et al. Post-operative re-irradiation with hyperthermia in locoregional breast cancer recurrence: temperature matters. Radiother Oncol. 2022;167:149–157.
  • Oei AL, Kok HP, Oei SB, et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. Adv Drug Deliv Rev. 2020;163–164:84–97.
  • Caffo O, Fellin G, Graffer U, et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer. 1996;78(5):1089–1097.
  • Henningsohn L, Wijkström H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002;62(2):215–225.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.